Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia

Despite the success of imatinib mesylate (IM) in the early chronic phase of chronic myeloid leukemia (CML), patients are resistant to IM and other kinase inhibitors in the later stages of CML. Our findings indicate that inhibition of Janus kinase 2 (Jak2) in Bcr–Abl+ cells overcomes IM resistance al...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Samanta, A, Perazzona, B, Chakraborty, S, Sun, X, Modi, H, Bhatia, R, Priebe, W, Arlinghaus, R
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2011
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3072513/
https://ncbi.nlm.nih.gov/pubmed/21183952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2010.287
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller